[Skip to Content]
Access to paid content on this site is currently suspended due to excessive activity being detected from your IP address 34.238.190.122. Please contact the publisher to request reinstatement.
[Skip to Content Landing]
1.
Kamholz SL. Pulmonary and cardiovascular consequences of smoking.  Med Clin North Am. 2004;88(6):1415-143015464105PubMedGoogle ScholarCrossref
2.
Pauwels RA, Rabe KF. Burden and clinical features of chronic obstructive pulmonary disease (COPD).  Lancet. 2004;364(9434):613-62015313363PubMedGoogle ScholarCrossref
3.
 Number of deaths from each cause, by 10-year age groups, race, and sex: United States, 2005. Centers for Disease Control and Prevention National Vital Statistics Web site. http://205.207.175.93/VitalStats/TableViewer/tableView.aspx?ReportId=26044. Accessed November 30, 2011
4.
Danaei G, Ding EL, Mozaffarian D,  et al.  The preventable causes of death in the United States: comparative risk assessment of dietary, lifestyle, and metabolic risk factors.  PLoS Med. 2009;6(4):e100005819399161PubMedGoogle ScholarCrossref
5.
Mokdad AH, Marks JS, Stroup DF, Gerberding JL. Actual causes of death in the United States, 2000.  JAMA. 2004;291(10):1238-124515010446PubMedGoogle ScholarCrossref
6.
Novotny M, Merli F, Weisler D, Fencl M, Saeed T. Fractionation and capillary gas chromatographic–mass spectrometric characterization of the neutral components in marijuana and tobacco smoke condensates.  J Chromatogr A. 1982;238(1):141-150Google ScholarCrossref
7.
Fligiel SE, Roth MD, Kleerup EC, Barsky SH, Simmons MS, Tashkin DP. Tracheobronchial histopathology in habitual smokers of cocaine, marijuana, and/or tobacco.  Chest. 1997;112(2):319-3269266864PubMedGoogle ScholarCrossref
8.
Barsky SH, Roth MD, Kleerup EC, Simmons M, Tashkin DP. Histopathologic and molecular alterations in bronchial epithelium in habitual smokers of marijuana, cocaine, and/or tobacco.  J Natl Cancer Inst. 1998;90(16):1198-12059719080PubMedGoogle ScholarCrossref
9.
Roth MD, Arora A, Barsky SH, Kleerup EC, Simmons M, Tashkin DP. Airway inflammation in young marijuana and tobacco smokers.  Am J Respir Crit Care Med. 1998;157(3, pt 1):928-9379517614PubMedGoogle ScholarCrossref
10.
Tashkin DP, Baldwin GC, Sarafian T, Dubinett S, Roth MD. Respiratory and immunologic consequences of marijuana smoking.  J Clin Pharmacol. 2002;42(11):(suppl)  71S-81S12412839PubMedGoogle Scholar
11.
Tetrault JM, Crothers K, Moore BA, Mehra R, Concato J, Fiellin DA. Effects of marijuana smoking on pulmonary function and respiratory complications: a systematic review.  Arch Intern Med. 2007;167(3):221-22817296876PubMedGoogle ScholarCrossref
12.
Hall W, Degenhardt L. Adverse health effects of non-medical cannabis use.  Lancet. 2009;374(9698):1383-139119837255PubMedGoogle ScholarCrossref
13.
Tashkin DP. Does cannabis use predispose to chronic airflow obstruction?  Eur Respir J. 2010;35(1):3-520044454PubMedGoogle ScholarCrossref
14.
 Results from the 2008 National Survey on Drug Use and Health: National Findings. HHS Publication SMA 09-4434. Substance Abuse and Mental Health Services Administration Web site. http://www.oas.samhsa.gov/NSDUH/2k8NSDUH/2k8results.cfm. 2009. Accessed November 30, 2011
15.
Joy JE, ed, Watson SJ, ed, Benson JA, edMarijuana and Medicine: Assessing the Science Base. Washington, DC: National Academies Press; 1999
16.
 Cannabis and cannabinoids. National Cancer Institute Web site. http://www.cancer.gov/cancertopics/pdq/cam/cannabis/healthprofessional. 2011. Accessed November 30, 2011
17.
Hughes GH, Cutter GR, Donahue R,  et al.  Recruitment in the Coronary Artery Disease Risk Development in Young Adults (CARDIA) study.  Control Clin Trials. 1987;8(4):(suppl)  68S-73S3440391PubMedGoogle ScholarCrossref
18.
Friedman GD, Cutter GR, Donahue RP,  et al.   CARDIA: study design, recruitment, and some characteristics of the examined subjects.  J Clin Epidemiol. 1988;41(11):1105-11163204420PubMedGoogle ScholarCrossref
19.
Wagenknecht LE, Burke GL, Perkins LL, Haley NJ, Friedman GD. Misclassification of smoking status in the CARDIA study: a comparison of self-report with serum cotinine levels.  Am J Public Health. 1992;82(1):33-361536331PubMedGoogle ScholarCrossref
20.
Hancox RJ, Poulton R, Ely M,  et al.  Effects of cannabis on lung function: a population-based cohort study.  Eur Respir J. 2010;35(1):42-4719679602PubMedGoogle ScholarCrossref
21.
American Thoracic Society.  Standardization of spirometry, 1994 update.  Am J Respir Crit Care Med. 1995;152(3):1107-11367663792PubMedGoogle ScholarCrossref
22.
Miller MR, Hankinson J, Brusasco V,  et al; ATS/ERS Task Force.  Standardisation of spirometry.  Eur Respir J. 2005;26(2):319-33816055882PubMedGoogle ScholarCrossref
23.
Kelly FJ, Fussell JC. Air pollution and airway disease.  Clin Exp Allergy. 2011;41(8):1059-107121623970PubMedGoogle ScholarCrossref
24.
 Air quality monitoring information: air quality statistics by city, 2009. US Environmental Protection Agency Web site. http://www.epa.gov/airtrends/factbook.html. Accessed November 30, 2011
25.
Marrie RA, Dawson NV, Garland A. Quantile regression and restricted cubic splines are useful for exploring relationships between continuous variables.  J Clin Epidemiol. 2009;62(5):511-517, e119135859PubMedGoogle ScholarCrossref
26.
Anthonisen NR, Connett JE, Kiley JP,  et al.  Effects of smoking intervention and the use of an inhaled anticholinergic bronchodilator on the rate of decline of FEV1: the Lung Health Study.  JAMA. 1994;272(19):1497-15057966841PubMedGoogle ScholarCrossref
27.
Sherman MP, Roth MD, Gong H Jr, Tashkin DP. Marijuana smoking, pulmonary function, and lung macrophage oxidant release.  Pharmacol Biochem Behav. 1991;40(3):663-6691666925PubMedGoogle ScholarCrossref
28.
Bloom JW, Kaltenborn WT, Paoletti P, Camilli A, Lebowitz MD. Respiratory effects of non-tobacco cigarettes.  Br Med J (Clin Res Ed). 1987;295(6612):1516-15183122882PubMedGoogle ScholarCrossref
29.
Sherrill DL, Krzyzanowski M, Bloom JW, Lebowitz MD. Respiratory effects of non-tobacco cigarettes: a longitudinal study in general population.  Int J Epidemiol. 1991;20(1):132-1372066211PubMedGoogle ScholarCrossref
30.
Taylor DR, Poulton R, Moffitt TE, Ramankutty P, Sears MR. The respiratory effects of cannabis dependence in young adults.  Addiction. 2000;95(11):1669-167711219370PubMedGoogle ScholarCrossref
31.
Moore BA, Augustson EM, Moser RP, Budney AJ. Respiratory effects of marijuana and tobacco use in a U.S. sample.  J Gen Intern Med. 2005;20(1):33-3715693925PubMedGoogle ScholarCrossref
32.
Aldington S, Williams M, Nowitz M,  et al.  Effects of cannabis on pulmonary structure, function and symptoms.  Thorax. 2007;62(12):1058-106317666437PubMedGoogle ScholarCrossref
33.
Tashkin DP, Calvarese BM, Simmons MS, Shapiro BJ. Respiratory status of seventy-four habitual marijuana smokers.  Chest. 1980;78(5):699-7067428453PubMedGoogle ScholarCrossref
34.
Tashkin DP, Simmons MS, Chang P, Liu H, Coulson AH. Effects of smoked substance abuse on nonspecific airway hyperresponsiveness.  Am Rev Respir Dis. 1993;147(1):97-1038420440PubMedGoogle ScholarCrossref
35.
Tashkin DP, Simmons MS, Sherrill DL, Coulson AH. Heavy habitual marijuana smoking does not cause an accelerated decline in FEV1 with age.  Am J Respir Crit Care Med. 1997;155(1):141-1489001303PubMedGoogle ScholarCrossref
36.
Tashkin DP, Coulson AH, Clark VA,  et al.  Respiratory symptoms and lung function in habitual heavy smokers of marijuana alone, smokers of marijuana and tobacco, smokers of tobacco alone, and nonsmokers.  Am Rev Respir Dis. 1987;135(1):209-2163492159PubMedGoogle Scholar
Original Contribution
January 11, 2012

Association Between Marijuana Exposure and Pulmonary Function Over 20 Years

Author Affiliations

Author Affiliations: Department of Epidemiology and Biostatistics (Drs Pletcher and Vittinghoff and Mr Lin) and Division of General Internal Medicine, Department of Medicine (Dr Pletcher), University of California, San Francisco; Asthma-COPD Program, Division of Pulmonary and Critical Care Medicine, Northwestern University Feinberg School of Medicine, Chicago, Illinois (Dr Kalhan); Department of Surgery (Dr Richman) and Division of Preventive Medicine (Drs Safford and Kertesz), University of Alabama at Birmingham; Center for Surgical, Medical and Acute Care Research and Transitions, Veterans Affairs Medical Center, Birmingham (Drs Richman and Kertesz); and Division of Research, Kaiser Permanente of Northern California, Oakland (Dr Sidney).

JAMA. 2012;307(2):173-181. doi:10.1001/jama.2011.1961
Abstract

Context Marijuana smoke contains many of the same constituents as tobacco smoke, but whether it has similar adverse effects on pulmonary function is unclear.

Objective To analyze associations between marijuana (both current and lifetime exposure) and pulmonary function.

Design, Setting, and Participants The Coronary Artery Risk Development in Young Adults (CARDIA) study, a longitudinal study collecting repeated measurements of pulmonary function and smoking over 20 years (March 26, 1985-August 19, 2006) in a cohort of 5115 men and women in 4 US cities. Mixed linear modeling was used to account for individual age-based trajectories of pulmonary function and other covariates including tobacco use, which was analyzed in parallel as a positive control. Lifetime exposure to marijuana joints was expressed in joint-years, with 1 joint-year of exposure equivalent to smoking 365 joints or filled pipe bowls.

Main Outcome Measures Forced expiratory volume in the first second of expiration (FEV1) and forced vital capacity (FVC).

Results Marijuana exposure was nearly as common as tobacco exposure but was mostly light (median, 2-3 episodes per month). Tobacco exposure, both current and lifetime, was linearly associated with lower FEV1 and FVC. In contrast, the association between marijuana exposure and pulmonary function was nonlinear (P < .001): at low levels of exposure, FEV1 increased by 13 mL/joint-year (95% CI, 6.4 to 20; P < .001) and FVC by 20 mL/joint-year (95% CI, 12 to 27; P < .001), but at higher levels of exposure, these associations leveled or even reversed. The slope for FEV1 was −2.2 mL/joint-year (95% CI, −4.6 to 0.3; P = .08) at more than 10 joint-years and −3.2 mL per marijuana smoking episode/mo (95% CI, −5.8 to −0.6; P = .02) at more than 20 episodes/mo. With very heavy marijuana use, the net association with FEV1 was not significantly different from baseline, and the net association with FVC remained significantly greater than baseline (eg, at 20 joint-years, 76 mL [95% CI, 34 to 117]; P < .001).

Conclusion Occasional and low cumulative marijuana use was not associated with adverse effects on pulmonary function.

×